Skip to main content
OpenTrials
Completed

NCT Number: NCT01903564

Fetal and Neonatal Magnetophysiology

Fetal research and clinical practice has been hampered by a lack of suitable investigational techniques. Currently, ultrasound is the only widely used method of studying fetal anatomy and physiology, but it has significant limitations for assessment of cardiac rhythm. The proposed study will allow us to investigate fetal magnetocardiography (fMCG) as a new tool for the study of normal and abnormal fetal heart rate and rhythm, with a goal of demonstrating probable benefit from use of the device in patients with serious fetal arrhythmia. We propose a study that will last 1-2 years and will provide data to aid in assessing the safety and effectiveness of fMCG for diagnosis and management of patients with abnormal fetal heart rate and rhythm. We hope that the data from the study will support a Humanitarian Device Exemption (HDE) application for the subject device. The safety and efficacy study designs are described below. High-risk subjects will undergo echocardiography as part of their routine clinical management, and our results will be compared to the echocardiography results, as well as with postnatal ECG, when available. (Since many arrhythmias resolve prior to birth, either due to resolution of disease or due to treatment, only a limited number of diseases allow postnatal comparison). For rhythms that persist after birth, the diagnostic utility of fMCG and echocardiography will be assessed by computing the sensitivity (Sn) and specificity (Sp) relative to postnatal ECG for the following prenatal modalities: (i) the fMCG, (ii) the original (referral) echo, (iii) if available, the in-lab echocardiogram at the time of the fMCG study. Secondary endpoints will assess changes in diagnosis and in clinical management due to the additional information provided by fMCG, compared to the information provided by echocardiography alone.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Normal subjects: normal, healthy adult women with uncomplicated pregnancies

High-risk cohort: The primary inclusion criterion is diagnosis of serious fetal arrhythmia, which is defined as sustained low or high heart rate. Low heart rate, or bradycardia, and high heart rate, or tachycardia, are based on normative values for gestation (usually below 110 -120 beats/min, or above 160-180 beats/min). Intermittent bradycardia and tachycardia are also important to detect because these arrhythmias may become incessant over the course of pregnancy and have implications for patient management. Abnormal repolarization, such as long QT syndrome (LQTS), is another important class of arrhythmia. Fetuses with a family history of LQTS or a suspicious rhythm (low heart rate, intermittent AV block, or ventricular tachycardia) will also be studied.

Exclusion criteria

The pregnant women subjects must by aged 18 or older. High-risk subjects cannot participate if their physician in consultation with the lead physician of the study does not grant permission for them to participate in the study due to risk of travel or other reason.

Treatment and study plan

Magnetocardiography

Device

recording of magnetic heart activity

Other names: MCG, fetal magnetocardiography

postnatal ECG

Device

postnatal ECG

Other names: electrocardiography

fetal echocardiography

Device

fetal echocardiography

Other names: Doppler ultrasound, M-mode ultrasound, 2d ultrasound

Primary outcomes

  1. Percentage of Subjects Experiencing Symptoms

    Time frame: 15-40 weeks' gestation

    Percentage of subjects experiencing symptoms

  2. Percentage of Subjects Experiencing Adverse Events Unrelated to Device

    Time frame: 15 weeks' gestation till up to 1 month after birth

    Percentage of subjects experiencing adverse events unrelated to device

  3. Number of Participants With Concordance of fMCG and Postnatal ECG for Diagnosis of Long QT Syndrome

    Time frame: Birth to age 1 week

    Number of Participants with Concordance of fMCG and Postnatal ECG for Diagnosis of Long QT Syndrome based on measurement of rate-corrected QT interval (QTc)

  4. Percentage of Subjects Experiencing Adverse Events Related to Device

    Time frame: 15 weeks' gestation till up to 1 month after birth

    Percentage of Subjects Experiencing Adverse Events Related to Device

Secondary outcomes

  1. Percentage of Fetuses With a Family History of Long QT Syndrome Who a Change in Diagnosis Due to fMCG

    Time frame: 15 weeks' gestation to birth

    Percentage of fetuses with a family history of long QT syndrome who a change in diagnosis due to fMCG

  2. Percentage of Fetuses With a Family History of Long QT Syndrome Who Had a Change in Management Due to fMCG

    Time frame: 15 weeks' gestation to birth

    Percentage of fetuses with a family history of long QT syndrome who had a change in management due to fMCG

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • Medical College of Wisconsin
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Shared Medical Technology, Inc.

Registry information

Important dates

Study start
2014
Primary completion
2016
Study completion
2018
First posted
Jul 19, 2013
Registry last updated
May 29, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.